The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy

Régis Bataille; Gaëtan Jégo; Nelly Robillard; Sophie Barillé-Nion; Jean-Luc Harousseau; Philippe Moreau; Martine Amiot; Catherine Pellat-Deceunynck

The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy

Haematologica. 2006 Sep;91(9):1234-40.

Authors

Régis Bataille¹, Gaëtan Jégo, Nelly Robillard, Sophie Barillé-Nion, Jean-Luc Harousseau, Philippe Moreau, Martine Amiot, Catherine Pellat-Deceunynck

Affiliation

¹ INSERM, U601, Nantes, France.

PMID: 16956823

Abstract

The aim of this review is to integrate non-exhaustive relevant data on the phenotype of human plasma cells (PC), including normal, reactive and malignant (multiple myeloma, MM) PC. This review focuses on (i) a universal marker of both normal and malignant plasma cells, CD138; (ii) markers related to malignancy i.e., CD19, CD27, CD28, and CD56; (iii) markers associated with signaling and severity of MM (CD45, CD221). Finally, this review presents data from normal PC up to human myeloma cell lines in order to: (i) define different entities of MM based on expression of CD19, CD20, CD27 and CD117; and (ii) identify new therapeutic targets.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antigens, CD / analysis
Biomarkers, Tumor
Drug Delivery Systems
Humans
Immunophenotyping
Multiple Myeloma / drug therapy*
Multiple Myeloma / pathology*
Plasma Cells* / cytology
Plasma Cells* / pathology

Substances

Antigens, CD
Biomarkers, Tumor